Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Companion Diagnostic Tests in Oncology market report explains the definition, types, applications, major countries, and major players of the Companion Diagnostic Tests in Oncology market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Siemens Healthcare
BioMerieux
Agilent
Agendia
QIAGEN
Genomic Health
Abbott
Illumina
Thermo Fisher
Roche
By Type:
Protein Detection
DNA Detection
By End-User:
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Companion Diagnostic Tests in Oncology Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Companion Diagnostic Tests in Oncology Outlook to 2028- Original Forecasts
-
2.2 Companion Diagnostic Tests in Oncology Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Companion Diagnostic Tests in Oncology Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Companion Diagnostic Tests in Oncology Market- Recent Developments
-
6.1 Companion Diagnostic Tests in Oncology Market News and Developments
-
6.2 Companion Diagnostic Tests in Oncology Market Deals Landscape
7 Companion Diagnostic Tests in Oncology Raw Materials and Cost Structure Analysis
-
7.1 Companion Diagnostic Tests in Oncology Key Raw Materials
-
7.2 Companion Diagnostic Tests in Oncology Price Trend of Key Raw Materials
-
7.3 Companion Diagnostic Tests in Oncology Key Suppliers of Raw Materials
-
7.4 Companion Diagnostic Tests in Oncology Market Concentration Rate of Raw Materials
-
7.5 Companion Diagnostic Tests in Oncology Cost Structure Analysis
-
7.5.1 Companion Diagnostic Tests in Oncology Raw Materials Analysis
-
7.5.2 Companion Diagnostic Tests in Oncology Labor Cost Analysis
-
7.5.3 Companion Diagnostic Tests in Oncology Manufacturing Expenses Analysis
8 Global Companion Diagnostic Tests in Oncology Import and Export Analysis (Top 10 Countries)
-
8.1 Global Companion Diagnostic Tests in Oncology Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Companion Diagnostic Tests in Oncology Export by Region (Top 10 Countries) (2017-2028)
9 Global Companion Diagnostic Tests in Oncology Market Outlook by Types and Applications to 2022
-
9.1 Global Companion Diagnostic Tests in Oncology Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Protein Detection Consumption and Growth Rate (2017-2022)
-
9.1.2 Global DNA Detection Consumption and Growth Rate (2017-2022)
-
9.2 Global Companion Diagnostic Tests in Oncology Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Pharmaceutical & Biotechnology Companies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Medical Device Companies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Research Institutes Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Companion Diagnostic Tests in Oncology Market Analysis and Outlook till 2022
-
10.1 Global Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.2.2 Canada Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.2.3 Mexico Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.2 UK Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.3 Spain Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.4 Belgium Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.5 France Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.6 Italy Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.7 Denmark Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.8 Finland Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.9 Norway Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.10 Sweden Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.11 Poland Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.12 Russia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.3.13 Turkey Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.2 Japan Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.3 India Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.4 South Korea Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.5 Pakistan Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.6 Bangladesh Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.7 Indonesia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.8 Thailand Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.9 Singapore Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.10 Malaysia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.11 Philippines Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.4.12 Vietnam Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.2 Colombia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.3 Chile Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.4 Argentina Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.5 Venezuela Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.6 Peru Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.7 Puerto Rico Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.5.8 Ecuador Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6.2 Kuwait Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6.3 Oman Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6.4 Qatar Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6.5 Saudi Arabia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.6.6 United Arab Emirates Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.7.2 South Africa Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.7.3 Egypt Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.7.4 Algeria Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Companion Diagnostic Tests in Oncology Consumption (2017-2022)
-
10.8.2 New Zealand Companion Diagnostic Tests in Oncology Consumption (2017-2022)
11 Global Companion Diagnostic Tests in Oncology Competitive Analysis
-
11.1 Siemens Healthcare
-
11.1.1 Siemens Healthcare Company Details
-
11.1.2 Siemens Healthcare Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Siemens Healthcare Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.1.4 Siemens Healthcare Companion Diagnostic Tests in Oncology Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 BioMerieux
-
11.2.1 BioMerieux Company Details
-
11.2.2 BioMerieux Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 BioMerieux Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.2.4 BioMerieux Companion Diagnostic Tests in Oncology Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Agilent
-
11.3.1 Agilent Company Details
-
11.3.2 Agilent Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Agilent Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.3.4 Agilent Companion Diagnostic Tests in Oncology Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Agendia
-
11.4.1 Agendia Company Details
-
11.4.2 Agendia Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Agendia Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.4.4 Agendia Companion Diagnostic Tests in Oncology Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 QIAGEN
-
11.5.1 QIAGEN Company Details
-
11.5.2 QIAGEN Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 QIAGEN Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.5.4 QIAGEN Companion Diagnostic Tests in Oncology Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Genomic Health
-
11.6.1 Genomic Health Company Details
-
11.6.2 Genomic Health Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Genomic Health Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.6.4 Genomic Health Companion Diagnostic Tests in Oncology Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Abbott
-
11.7.1 Abbott Company Details
-
11.7.2 Abbott Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Abbott Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.7.4 Abbott Companion Diagnostic Tests in Oncology Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Illumina
-
11.8.1 Illumina Company Details
-
11.8.2 Illumina Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Illumina Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.8.4 Illumina Companion Diagnostic Tests in Oncology Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Thermo Fisher
-
11.9.1 Thermo Fisher Company Details
-
11.9.2 Thermo Fisher Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Thermo Fisher Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.9.4 Thermo Fisher Companion Diagnostic Tests in Oncology Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Roche
-
11.10.1 Roche Company Details
-
11.10.2 Roche Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Roche Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
11.10.4 Roche Companion Diagnostic Tests in Oncology Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Companion Diagnostic Tests in Oncology Market Outlook by Types and Applications to 2028
-
12.1 Global Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Protein Detection Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global DNA Detection Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Pharmaceutical & Biotechnology Companies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Medical Device Companies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Research Institutes Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Companion Diagnostic Tests in Oncology Market Analysis and Outlook to 2028
-
13.1 Global Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.2.2 Canada Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.2.3 Mexico Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.2 UK Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.3 Spain Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.4 Belgium Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.5 France Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.6 Italy Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.7 Denmark Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.8 Finland Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.9 Norway Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.10 Sweden Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.11 Poland Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.12 Russia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.3.13 Turkey Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.2 Japan Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.3 India Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.4 South Korea Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.8 Thailand Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.9 Singapore Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.11 Philippines Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.2 Colombia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.3 Chile Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.4 Argentina Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.6 Peru Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6.3 Oman Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6.4 Qatar Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.7.2 South Africa Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.7.3 Egypt Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.7.4 Algeria Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Companion Diagnostic Tests in Oncology Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Companion Diagnostic Tests in Oncology
-
Figure of Companion Diagnostic Tests in Oncology Picture
-
Table Global Companion Diagnostic Tests in Oncology Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Companion Diagnostic Tests in Oncology Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Protein Detection Consumption and Growth Rate (2017-2022)
-
Figure Global DNA Detection Consumption and Growth Rate (2017-2022)
-
Figure Global Pharmaceutical & Biotechnology Companies Consumption and Growth Rate (2017-2022)
-
Figure Global Medical Device Companies Consumption and Growth Rate (2017-2022)
-
Figure Global Research Institutes Consumption and Growth Rate (2017-2022)
-
Figure Global Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Table North America Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure United States Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Canada Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Mexico Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table Europe Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure Germany Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure UK Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Spain Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Belgium Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure France Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Italy Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Denmark Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Finland Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Norway Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Sweden Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Poland Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Russia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Turkey Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table APAC Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure China Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Japan Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure India Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure South Korea Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Thailand Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Singapore Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Philippines Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table South America Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure Brazil Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Colombia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Chile Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Argentina Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Peru Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table GCC Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure Bahrain Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Oman Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Qatar Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table Africa Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure Nigeria Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure South Africa Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Egypt Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure Algeria Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table Oceania Companion Diagnostic Tests in Oncology Consumption by Country (2017-2022)
-
Figure Australia Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Companion Diagnostic Tests in Oncology Consumption and Growth Rate (2017-2022)
-
Table Siemens Healthcare Company Details
-
Table Siemens Healthcare Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Siemens Healthcare Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Siemens Healthcare Companion Diagnostic Tests in Oncology Product Portfolio
-
Table BioMerieux Company Details
-
Table BioMerieux Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMerieux Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table BioMerieux Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Agilent Company Details
-
Table Agilent Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Agilent Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Agilent Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Agendia Company Details
-
Table Agendia Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Agendia Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Agendia Companion Diagnostic Tests in Oncology Product Portfolio
-
Table QIAGEN Company Details
-
Table QIAGEN Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table QIAGEN Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table QIAGEN Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Genomic Health Company Details
-
Table Genomic Health Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genomic Health Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Genomic Health Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Abbott Company Details
-
Table Abbott Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Abbott Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Illumina Company Details
-
Table Illumina Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Illumina Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Illumina Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Thermo Fisher Company Details
-
Table Thermo Fisher Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Thermo Fisher Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Thermo Fisher Companion Diagnostic Tests in Oncology Product Portfolio
-
Table Roche Company Details
-
Table Roche Companion Diagnostic Tests in Oncology Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Companion Diagnostic Tests in Oncology Main Business and Markets Served
-
Table Roche Companion Diagnostic Tests in Oncology Product Portfolio
-
Figure Global Protein Detection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global DNA Detection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pharmaceutical & Biotechnology Companies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Medical Device Companies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Research Institutes Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Table North America Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure United States Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure Germany Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure China Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure Brazil Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Companion Diagnostic Tests in Oncology Consumption Forecast by Country (2022-2028)
-
Figure Australia Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Companion Diagnostic Tests in Oncology Consumption Forecast and Growth Rate (2022-2028)
-
